Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

Market News

Devangshu Datta: When central bankers become newsmakers

While the RBI and the Swiss National Bank made some surprising moves, the European Central Bank announced the details of its QE plan

Sebi asks Servotech promoters to make offer to buy more shares

The promoter group has to make the announcement within 45 days

Gold to remain elevated in the short term: analysts

Greece election and US Fed meet crucial events for the bullion market

De Beers to sell large size diamonds through forward contracts

Will sell +2 carat diamonds through the route for the first time

Sensex records highest weekly gain since June 2014

Rises 4.1% to end at a record 29,279 on ECB stimulus, IMF forecast

 

Back to Top